secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001140361-23-058648
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 3.02, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna raises $9.2M convertible debt, CEO resigns, Sanjeev Luther appointed
---------------------------------------------------------------------------

- Issued $9.2M principal of 12% senior convertible notes; initial close of ~$7.8M on Dec. 15, remainder by Jan. 15, 2024.
- Notes convertible at $1.9194/share; warrants for 9.58M shares at $1.43; 10.46M existing warrants repriced to $1.43.
- CEO Matthew Angel resigns effective Dec. 31, 2023, no disagreement; succeeded by Sanjeev Luther as President and CEO on Jan. 1, 2024.
- New CEO Luther: base salary $550K, signing bonus $75K, option for 1,685,218 shares, target bonus 50% of base.
- James Bristol appointed Chairman of the Board effective Dec. 19, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123058648/0001140361-23-058648-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123058648/ef20016457_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-058648

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer